In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...
Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...
Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient ...
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...
The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.
Hosted on MSN9d
I-Mab stock jumps 15% following pipeline updateShares of I-Mab (NASDAQ:IMAB) jumped 15% in midday trading Monday after the biotech company said it plans to focus on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback